Hemophagocytic Lymphohistiocytosis News and Research

RSS

Risk factors for COVID-19 in patients with hematological malignancies

Researchers investigate the risk factors present in individuals suffering from hematological malignancies and COVID-19.

26 May 2022

Multisystem inflammatory syndrome as a late complication in COVID-19 infected children

Researchers determined the immune signature of the multisystem inflammatory syndrome in children among hospitalized children diagnosed with SARS‐CoV‐2 infection.

16 Mar 2022

Impact of SARS-CoV-2 infection on human semen quality

A new review article aimed to extract, review and summarize these articles from the mentioned databases to determine the link between SARS-CoV-2 infection and semen quality.

3 Nov 2021

Decline in SARS-CoV-2 neutralizing antibodies and unique cytokine profile in severe COVID-19 patients

A new study has focused on antibody levels and cytokine profiles of COVID-19 patients with mild symptoms, pneumonia, and severe pneumonia.

21 Sep 2021

First cell-based gene therapy approved by the FDA for treating multiple myeloma

The U.S. Food and Drug Administration approved Abecma (idecabtagene vicleucel), a cell-based gene therapy to treat adult patients with multiple myeloma who have not responded to, or whose disease has returned after, at least four prior lines (different types) of therapy.

29 Mar 2021

Scientists discover potential strategy to prevent inflammation in COVID-19 patients

The COVID-19 pandemic continues to cause significant illness and death while treatment options remain limited. St. Jude Children's Research Hospital scientists have discovered a potential strategy to prevent life-threatening inflammation, lung damage and organ failure in patients with COVID-19. The research appeared online in the journal Cell.

19 Nov 2020

Study shows how combining two drugs may be an effective treatment for HLH

Scientists at St. Jude Children's Research Hospital, UCSF Benioff Children's Hospitals and Baylor College of Medicine are investigating how to best treat hemophagocytic lymphohistiocytosis (HLH), a rare immune disorder.

12 Jun 2020

Ruxolitinib shows promise in severe COVID-19

An anti-inflammatory drug Ruxolitinib has shown promising results in the treatment of severe coronavirus disease COVID-19. The study titled, “Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial,” was published as a pre-proof for the Journal of Allergy and Clinical Immunology.

31 May 2020

Transgenic mouse model of HLH may play key role in saving lives during COVID-19

A transgenic mouse developed at Cincinnati Children's to model the deadly childhood immune disease HLH (hemophagocytic lymphohistiocytosis) may play a key role in saving lives during the COVID-19 virus pandemic.

28 May 2020

Anti-inflammatory drug may improve respiratory function in some severe COVID-19 cases

A small study in Greece found that the clinically approved anti-inflammatory drug anakinra, used to treat rheumatoid arthritis, improved respiratory function in patients with severe coronavirus disease 2019 (COVID-19).

14 May 2020

COVID-19 could be causing potentially fatal inflammatory disease in children, doctors warn

Since the emergence of the coronavirus disease (COVID-19) in China in December 2019, health experts have cautioned that the disease is particularly serious in high-risk populations, including older adults, those with underlying diseases, and those who are immunocompromised. Now, doctors in the United Kingdom warn of a rare and severe inflammatory disease in children with COVID-19.

28 Apr 2020

Young patients with IBD have increased risk of severe viral infections

Young patients with inflammatory bowel disease are five times more likely than the general population to develop viral infections that can lead to hospitalization or permanent organ damage, a new study published in the UEG Journal has found.

5 Dec 2019

New textbook on mysterious and deadly cytokine storm syndrome

There's no telling where the call will come from, or when. But Randy Cron, M.D., Ph.D., professor of pediatrics and medicine at UAB, knows to expect them.

11 Nov 2019

Removing tumor's protective wall could help boost the effects of cancer treatments

Scientists may have found a way to pull down the protective wall that surrounds tumors, potentially re-exposing them to the killing power of the immune system and immunotherapy treatments, according to a study part funded by Cancer Research UK and published in EBioMedicine today (Monday).

26 Aug 2019

AACR Annual Meeting 2019 Highlighted Latest Advances in Cancer Research

On Friday, March 29 to Wednesday, April 3, the Georgia World Congress Center in Atlanta, Georgia, hosted the AACR Annual Meeting 2019.

From 10x Genomics, Inc. 4 Apr 2019

Researchers caution that expediting HLH treatment may miss underlying cancers

Physicians who specialize in a devastating and aggressive immune disorder called hemophagocytic lymphohistiocytosis report in a new study that extra care should be taken to ensure an HLH diagnosis doesn't obscure possible underlying cancers.

1 Oct 2018

Researchers find STAT3 as therapeutic target for chronic active EBV infection

Tokyo Medical and Dental University study shows that ruxolitinib-induced inhibition of STAT3 activity blocks survival and reduces pro-inflammatory cytokine production in Epstein-Barr virus (EBV)-infected clonally proliferating T- or NK-cells in Chronic active Epstein-Barr virus infection.

20 Aug 2018

Experimental treatment tempers HLH, MS symptoms in mouse models, study shows

Immune diseases like multiple sclerosis and hemophagocytic lymphohistiocytosis unleash destructive waves of inflammation on the body, causing death or a lifetime of illness and physical impairment.

23 May 2017

Doctors use targeted molecular drugs to treat fatal cancerous blood syndromes

Genomic testing of biopsies from patients with deadly, treatment-resistant cancerous blood syndromes called histiocytoses allowed doctors to identify genes fueling the ailments and use targeted molecular drugs to successfully treat them.

16 Feb 2017

People with viral infections and identical gene mutations may be prone to hyperinflammatory disorder

A group of people with fatal H1N1 flu died after their viral infections triggered a deadly hyperinflammatory disorder in susceptible individuals with gene mutations linked to the overactive immune response, according to a study in The Journal of Infectious Diseases.

25 Nov 2015